Thyreogen
Key Facts: Thyreogen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
The bioregulator theory behind Thyreogen is that very short, tissue-specific peptides can slip into cells, bind to particular stretches of DNA in the gene promoters of that organ, and nudge gene expression back toward a younger, healthier pattern - in this case, the thyroid. For Thyreogen specifically, vendors claim it normalizes thyroid cell metabolism and the output of T3, T4 and calcitonin. It is worth being clear that this organ-targeting, DNA-binding mechanism is Khavinson's hypothesis, supported mostly by his own group, not an independently established pathway. No receptor or signaling cascade specific to Thyreogen has been mapped in the way you would expect for an approved drug.
Research Summary
The general Khavinson peptide program has decades of Russian publications and some peer-reviewed reviews, for example work in Advances in Gerontology arguing short peptides act as epigenetic regulators that bind DNA and shift methylation patterns with age. But almost none of that evidence is about Thyreogen as a specific product. There are no registered, randomized, placebo-controlled human trials of Thyreogen for thyroid disease, and the existing data sits inside a single research lineage with little independent replication, which means findings should be read as hypothesis-generating rather than proof. Animal and review-level work on the broader peptide family reports geroprotective effects like longer rodent lifespan and restored endocrine function, but extrapolating that to a calf-thyroid capsule treating human thyroid conditions is a leap the data does not support. If you have a real thyroid problem, this is not a substitute for tested treatment. Honest bottom line: low-quality, single-source evidence and no proper clinical proof.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Thyroid bioregulator. May affect thyroid hormone levels - use with caution.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●May affect thyroid hormone levels
- ●Limited safety data outside Russia
- ●Not FDA approved
References
- https://pubmed.ncbi.nlm.nih.gov/22708439/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9032300/
- https://link.springer.com/article/10.1134/S2079057012040091
Research This Peptide Further
Frequently Asked Questions
What does Thyreogen do?
Thyreogen is not a single drug peptide but a 'cytomax' supplement - a mix of short peptides extracted from calf thyroid tissue, sold as part of Professor Vladimir Khavinson's Russian bioregulator line and marketed for thyroid support. There is no defined sequence on the label, no FDA approval, and no independent peer-reviewed clinical trial behind it. Treat the marketing claims as unproven.
How does Thyreogen work?
The bioregulator theory behind Thyreogen is that very short, tissue-specific peptides can slip into cells, bind to particular stretches of DNA in the gene promoters of that organ, and nudge gene expression back toward a younger, healthier pattern - in this case, the thyroid. For Thyreogen specifically, vendors claim it normalizes thyroid cell metabolism and the output of T3, T4 and calcitonin. It is worth being clear that this organ-targeting, DNA-binding mechanism is Khavinson's hypothesis, supported mostly by his own group, not an independently established pathway. No receptor or signaling cascade specific to Thyreogen has been mapped in the way you would expect for an approved drug.
Is Thyreogen FDA approved?
No, Thyreogen is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Thyreogen?
Reported side effects include: Generally well-tolerated, May affect thyroid hormone levels, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Thyreogen?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Thyreogen or used in similar applications.
Livagen
PreclinicalLivagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
BioregulatorsOvagen
PreclinicalOvagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
BioregulatorsCortagen
PreclinicalCortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.
BioregulatorsVesugen
PreclinicalVesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.
BioregulatorsChonluten
PreclinicalChonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
BioregulatorsCrystagen
PreclinicalCrystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).
BioregulatorsWant updates on Thyreogen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.